Neumora Therapeutics’ Experimental Drug Demonstrates Weight Loss in Preclinical Studies
Synopsis
- Neumora said that NMRA-215 demonstrated weight loss of up to 19% as a monotherapy and 26% in combination with semaglutide.
- The company now plans to initiate an early-stage clinical study for the experimental drug in the first quarter of 2026.
Neumora Therapeutics, Inc. (NMRA) on Monday announced positive data from preclinical studies for its experimental weight-loss therapy NMRA-215.
The company said that NMRA-215 demonstrated weight loss of up to 19% as a monotherapy and 26% in combination with Semaglutide in mice. Semaglutide is the active ingredient in Novo Nordisk’s popular weight-loss drug Wegovy.
Plans Ahead
The company now plans to initiate an early-stage clinical study for the experimental drug in the first quarter of 2026.
Shares of the company jumped about 22% in the pre-market session at the time of writing.
Get updates to this developing story <directly on Stocktwits.<
Stay updated with all the latest Business News, including market trends, Share Market News, stock updates, taxation, IPOs, banking, finance, real estate, savings, and investments. Track daily Gold Price changes, updates on DA Hike, and the latest developments on the 8th Pay Commission. Get in-depth analysis, expert opinions, and real-time updates to make informed financial decisions. Download the Asianet News Official App from the Android Play Store and iPhone App Store to stay ahead in business.